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878-2 Oral Rapamycin in Patients Undergoing Coronary Stent 
Therapy: Final Results of the ORAR Study (Oral 
Rapamycin in Argentina)
Alfredo E. Rodriguez, Máximo Rodriguez Alemparte, Carlos Fernandez Pereira, César F. 
Vigo, Claudio LLauradó, Miguel Russo Felsen, Antonio Pocovi, David Vetcher, Otamendi 
Hospital, Buenos Aires, Argentina, Argentine Society for Cardiac Intervention, Buenos 
Aires, Argentina
Background:We previously reported (ACC03) preliminary findings of this study suggest-
ing that high concentration of rapamycin blood level (>8ng/ml) is associated with a trend
to low late loss and restenosis rate in patients(pts) undergoing coronary stent therapy.
Methods:From December 2001 to February 2003, 76 pts with 103 arteries treated with
stents were included in phase I (34 pts/49 arteries) and phase II (42 pts/54 arteries) of
the ORAR study. A loading dosis of 6 mg of oral rapamycin was administered inmediately
after stent deployment in all pts. In Phase I, 2 mg of oral rapamycin was given daily dur-
ing 28 days. In Phase II 3 mg daily of rapamycin was given plus 160 mg of diltiazem dur-
ing 28 days. Rapamycin blood levels were measured at third week in all pts.Cholesterol
and triglycerides were evaluated before and after one month of treatment. Statins were
given as well clopidogrel in all pts during six months. Angiographic binary restenosis, late
loss, target lesion revascularization, treatment compliance,side effects and optimal con-
centration of the drug were analized. At the present time 6 month angiographic follow up
data were available in 82.5% of the arteries.
Results:Baseline clinical characteristics showed diabetes 25.2%, type B1, B2 and C
lesions in 81%, reference vessel size <2.9 mm in 37% and with a lesion lenght of 11.1 +
0.8 mm. Minor side effects were present in 25% of the patients but only three discontinue
the treatment (4%). Follow up quantitative angiographic data showed that pts having > 8
ng/ml compared with those having < 8 ng /ml had lower late loss ( 0.65 mm vs. 1.11 mm
respectively p < 0.031), binary in stent restenosis (6.2% vs.23% respectively p < 0.039)
and better MLD ( 2.16 mm vs.1.71 respectively p< 0.054) . Pearson test showed strong
correlation between blood level of the drug and late loss ( r<0.001) Minor adverse side
effects had a trend to increased with high blood concentration of the drug (p=0.083).
Conclusions: Oral rapamycin after coronary stent deployment in those pts who reached
high concentration of the drug are associated with low late loss, binary restenosis and
better MLD in the follow up angiogram. A randomized drug / placebo study is ongoing
(ORAR II).
11:00 a.m.
878-3 Subgroup Analysis of the Impact of the Glycoprotein IIb/
IIIa Inhibitor Abciximab in Patients Undergoing Elective 
Stent Placement >2 Hours After Treatment With a 600 
Milligram Loading Dose of Clopidogrel: Results From 
the ISAR REACT Trial
Peter B. Berger, Adnan Kastrati, Julinda Mehilli, Helmut Schuhlen, Josef Dirschinger, 
Franz Dotzer, Jurrien M. ten Berg, Franz-Josef Neumann, Hildegard Bollwein, Christian 
Volmer, Meinrad Gawaz, Albert Schomig, Mayo Clinic, Rochester, MN, Deutsches 
Herzzentrum Munchen, Munich, Germany
ISAR REACT was designed to evaluate whether the glycoprotein IIb/IIIa inhibitor abcix-
imab is beneficial in low and intermediate risk patients undergoing elective percutaneous
coronary intervention (PCI) with a stent after maximal inhibition of aggregation had been
achieved after pretreatment with a high, 600 mg loading dose of clopidogrel. The fre-
quency of events among subgroups, including the 20% of pts with non-insulin dependent
diabetes (n=441), has not been reported. (See figure for results)
Conclusion: In these subgroups of varying risk among the low to intermediate risk
patients who undergo elective PCI after pretreatment with a high loading dose of clopi-
dogrel >2 hours prior to elective PCI, the results suggest that, as in the entire trial glyco-
protein IIb/IIIa inhibitor abciximab is associated with no clinically measurable benefit
within the first 30 days.
11:15 a.m.
878-4 Qualitative and Quantitative Analysis of Saphenous 
Vein Graft Plaque Debris Within the MedNova 
CardioShield™ Embolic Capture Device
David R. Holmes, Jr., on behalf of the CAPTIVE Pivotal Study Investigators, Deena 
Weber, Frank Kolodgie, Renu Virmani, Mayo Clinic, Rochester, MN, Armed Forces 
Institute of Pathology, Washington, DC
Background: There is limited information on the composition of atheroembolic debris
released during stent treatment of diseased aorto-coronary bypass saphenous vein
grafts (SVG). Intravascular filtration systems provide a unique opportunity to analyze
plaque debris captured following SVG intervention.
Device Description: The CardioShield embolic capture device consists of a polyurethane
membrane having 140 micron distal perfusion holes, two proximal entry ports, and an
internal self-expanding nitinol support system. The filter is delivered over a pre-placed
0.014” filter delivery wire, allowing independent wire movement, and is deployed distal to
the SVG target lesion. Following stenting, the filter is removed using a retrieval catheter
system.
Methods: One-hundred sixteen (116) filter devices utilized during stent treatment of 113
SVG lesions were submitted for histologic and morphometric analysis. Filter contents
were removed, embedded, and microscopically evaluated to establish a profile of the
contained embolic debris.
Results: Atheroembolic debris was collected in 95 (82%) of the 116 devices. In the
devices containing debris, 72 (76%) demonstrated macrophage foam cells, 46 (48%) had
smooth muscle cells, and 85 (90%) had necrotic core. Other identified debris included
platelets/fibrin in 89 (94%), cholesterol clefts in 56 (59%), and collagen/elastin in 51
(54%). Use of a platelet glycoprotein IIb/IIIa inhibitor did not affect a difference in fre-
quency, amount or composition of embolic debris. Morphometric measurements on
1,193 particles yielded an average particle size of 0.11 mm2 and minimal/maximal areas
of 0.02 mm2 and 0.50 mm2, respectively. The area of the largest particle was 3.47 mm2.
The majority of devices contained particles _ 0.1 mm2.
Conclusions: During treatment of SVG disease, embolic debris is frequently liberated and
seen in the majority of patients. The debris typically consists of necrotic core, macroph-
age foam cells, and platelet/fibrin aggregates. This filter system is effective at capturing
released embolic particles of variable size and composition.
11:30 a.m.
878-5 Provisional Versus Systematic T Stenting: Insights 
From a Large Prospective Single-Center Database
André Kokis, Gunasekaran Sengottuvel, Thierry Lefèvre, Samer Mansour, Yves Louvard, 
Pierre Dumas, Christophe Loubeyre, Marie-Claude Morice, Institut Cardiovasculaire 
Paris Sud, Massy, France
Background: Although numerous studies on PCI in bifurcation lesions are available, the
superiority of either provisional or systematic T stenting has not been conclusively
proven. Our registry is a large, single centre database on patients undergoing PCI in cor-
onary bifurcations and will give insights on this issue .
Methods. Our registry of PCI in bifurcation lesions started in November 1995 including
patients who undergo treatment for true and false bifurcation lesions. We compared from
this prospective database the in-hospital and 6 months outcome following systematic ver-
sus provisional T stenting for bifurcation lesions.
Results: Of the 1149 patients, provisional T stenting strategy was the most commonly
adopted strategy with 837 patients. In the provisional T-stenting group, 25.6 % patients
also required a stent in the side branch. 297 received systematic T stenting which was
performed using Type A treatment (Systematic T stenting of the side branch first) in 8.3
%, Type C treatment (Culotte) in 1.9 % and Type D treatment (V stenting) in 6 %. Base-
line characteristics were similar in both groups. The angiographic success (residual
stenosis < 50 %) was 93.6 % vs 91.8% in the main branch and 90.6 % vs 84.6% in the
side branch in the systematic versus provisional T stenting group. In the provisional T
stenting group compared to systematic T stenting group all measured parameters were
significantly lower: in-hospital MACE (3.2% vs 7.4%, p = 0.008), in- hospital death (0.1%
vs 1.3%, p = 0.02), sub-acute thrombosis (0.1 % vs 1.7 %, p = 0.007), need for urgent
CRP IL-6 IL-1RA sCD40L
Pre-PCI 9.4±14 6.9±10 545±378 0.80±0.46
10 Minutes Post PCI 8.9±13 7.81±11 594±421 1.08±0.86
P Value 0.82 0.60 0.45 0.01
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repeat-PCI (1% vs 2.7 %, p = 0.005), need for urgent CABG (0.1% vs 1.3 %, p = 0.03),
seven months MACE (1% vs 3.1 %, p = 0.029), seven months TVR (11 % vs 19.9%, p =
0.001), combined MACE /TVR at seven months (14.9 % vs 26.9 %, p = 0.001) and death
at seven months (1 % vs 3.1 %, p = 0.029).
Conclusion: Analysis of our large database of bifurcation lesions shows that provisional
T stenting is the sole modifiable predictor associated with a reduction in target vessel
revascularization as well as MACE and should be the preferred strategy for coronary
bifurcation lesion PCI.
11:45 a.m.
878-6 Stenting Under Intravascular Ultrasound Guidance of 
Coronary Bifurcation Lesions With a New Device 
Allowing Provisional Side Branch Treatment
Wim J. Vander Giessen, Jurgen R. Ligthart, Pieter C. Smits, Pim J. de Feyter, George 
Sianos, Thierry Lefèvre, Patrick W. Serruys, Thoraxcenter, Erasmus MC, Rotterdam, The 
Netherlands
Background: A new stent (MULTI-LINK FRONTIER) was developed for coronary bifur-
cation lesions. It is an 18 mm stent premounted on a delivery system with 2 balloons. The
device is positioned by pushing it up to the carina of the bifurcation. Simultaneous infla-
tion of the balloons deploys the main branch (MB) stent and opens up a portal to the side
branch (SB). We studied intravascular ultrasound (IVUS) parameters and their relation to
procedural success and 6-month outcome.
Methods: Patients with (un)stable angina pectoris and de novo or restenotic (no previous
stent) bifurcation lesion between 2.5 and 4 mm in diameter for the main branch and
>2.0mm for the side branch were eligible. Exclusion criteria were angiographic severe
calcification, thrombus or left main lesion. Pre-, post-, and at follow-up IVUS was per-
formed in MB and SB using a 30 MHz catheter and automated pull-back.
Results: 18 patients were included: male 14, age 62 (13) year. The LAD/diag bifurcation
was the target lesion in 17/18. After IVUS and mandatory predilatation stent implantation
was successful in 16 (89%). Failure to wire the SB or to position the catheter in phase
with the SB were the cause. Implantation at the carina succeeded in 12/16 (75%). The
cases with ”carina failure” had longer segments with calcified plaque proximal to the car-
ina than cases with “carina success” (25 (14) vs 11 (11) mm; P<0.05) as assessed by
IVUS. The presence of calcium per se, or its circumferential angle or whether superficial
or deep was not associated with carina failure. Carina failure resulted in (partial) overlap
of the stent with the ostium of the SB in 75%. Carina failure or SB overlap was not asso-
ciated with SB restenosis. MLA by IVUS pre-, post-, and at 6 months FU was 2.3 (1.2)
mm2, 7.3 (2.2) mm2, and 4.2 (1.0) mm2, resp. (P<0.05). At FU there were no deaths or
MI’s. Target vessel revascularization occurred in 3 patients (16.6%). Angiographic rest-
enosis (>50% DS) occurred in 18.8% in the Frontier stent MB and in 12.5% in the SB,
overall 31.3%.
Conclusion: This bifurcation stent can be implanted in about 90% of lesions, with prom-
ising 6 months adverse event rate. Longer proximal calcified segment is associated with
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880-1 Repeat Intracoronary Gamma Radiation for Patients 
With In-Stent Restenosis Who Failed Radiation 
Therapy: Results From the Re-WRIST Clinical Trial
Ron Waksman, Andrew E. Ajani, Rebecca Torguson, Donna J. Whitman, Daniel A. 
Canos, Regina Deible, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Kenneth 
M. Kent, Joseph Lindsay, Washington Hospital Center, Washington, DC
Background: Intracoronary radiation (IR) is an effective therapy for preventing the recur-
rence of in-stent restenosis (ISR). However, nearly 20% of patients enrolled in radiation
studies required repeat revascularization to the irradiated site. Re-WRIST is a registry
evaluating the safety and efficacy of retreatment with IR.
Methods: Thirty pts (31 lesions) with ISR at the previously irradiated segment and who
failed a subsequent angioplasty without radiation were eligible for retreatment with IR.
The Checkmate radiation system using Ir-192 seeds was udes, and the repeat was pre-
scribed dose was 15 Gy at 2 mm. The antiplatlet regimen post procedure was lifelong
aspirin and at least 6 months of clopidogrel.
Results: Pts mean age was 65±7.9 yrs, 67% were males, 52% were diabetic, and 90%
had CABG. Lesions were in native coronaries 67.7%, saphenous vein grafts 29.0%, and
the left internal mammary 3.3%. Time between radiation treatments was 16.4±8.7 mos
and the number of interventions to the target lesion was 5.2±3.5 (range 3-20). The lesion
length was 21.74±14.25 mm. At 9 mos, the major adverse cardiac events rate was 36%,
target lesion revascularization 32%, MI 0%, and deaths 4%. QCA at 9 months demon-
strated a restenosis rate of 35%. There was one late total occlusion and no angiographic
complications (evidence of aneurysm, fibrosis, perforation) in any of the pts.
Conclusions: Repeat radiation to the same site using Ir-192 for refractory ISR is safe
and should be considered an option in this difficult patient subset. 
10:45 a.m.
880-2 Randomized Comparison of Rotational Atherectomy 
and Cutting Balloon Angioplasty Followed by Radiation 
Therapy With a 188Re-MAG3-Filled Balloon in the 
Treatment of Diffuse In-Stent Restenosis
Seong-Wook Park, Seung-Whan Lee, Young-Hak Kim, Ki-Hoon Han, Cheol Whan Lee, 
Myeong-Ki Hong, Jae-Joong Kim, Seung-Jung Park, Asan Medical Center, Seoul, South 
Korea
Background: Randomized comparison of rotablation atherectomy (RA) and cutting bal-
loon angioplasty (CB), followed by beta-radiation for in-stent restenosis (ISR) has not
been reported.
Methods: This randomized controlled study was conducted to compare the efficacy of
RA (n=58) with CB (n=55) prior to beta-radiation therapy with a rhenium-188-mercap-
toacetyltriglycine (188Re-MAG3)-filled balloon for diffuse in-stent restenosis (ISR). The
radiation dose was 18 Gy at a depth of 1.0 mm into the vessel wall.
Results: The baseline clinical and angiographic characteristics were similar between the
2 groups. The lesion length was 21.0±11.2 mm in the RA group and 20.8±10.2 mm in the
CB group (p=0.77). Radiation was delivered successfully to all patients. Adverse events
including myocardial infarction, death, or stent thrombosis did not occurred during the 9-
month follow-up period. Six months angiographic follow-up was obtained in 88 patients
(78%) and the rates of angiographic restenosis was not statistically different between the
RA group (13%, 6/46) and the CB group (12%, 5/42)(p=0.87). The risk of a target lesion
revascularization or a major adverse cardiac event was similar between two groups (RA
group vs CB group: 3.4% vs 3.6%, p=0.94) during 9-month follow-up period.
Conclusions: Concomitant treatment of RA or CB with beta-irradiation using a 188Re-
MAG3-filled balloon for diffuse ISR was safe and had a similarly favorable angiographic
and clinical outcomes.
11:00 a.m.
880-3 Histopathological Characteristics of Edge Restenosis 
After Intracoronary Brachytherapy for In-Stent 
Restenosis
Masaharu Okada, Hideo Tamai, Eisho Kyo, Kunihiko Kosuga, Tatsuhiko Hata, Takuji 
Nakamura, Shinya Fujita, Takafumi Tsuji, Shinsaku Takeda, Nobutoyo Masunaga, 
Katsuyuki Hasegawa, Seiichiro Motohara, Hiromu Uehata, Shiga Medical Center for 
Adults, Moriyama, Japan
Background: Histopathology of edge restenosis following intracoronary brachytherapy
(BT) has not been fully evaluated in humans. The purpose of this study was to clarify the
histopathological characteristics of edge restenosis following BT by examining the speci-
mens obtained from directional coronary atherectomy (DCA). Methods: Eight edge rest-
enosis lesions which developed in native coronary arteries after BT with the beta-emitting
32P source wire were obtained by DCA and were compared with the restenosis lesion
which developed after ordinary balloon angioplasty without BT (R, 6 lesions). Edge rest-
enosis was defined as a lesion which developed 5 mm proximal or distal to either edge of
32P source wire. Mean interval from BT to edge restenosis was 242±28 days. Specimens
retrieved by DCA were immediately placed in 10% buffered formalin, processed for paraf-
fin embedding and stained with hematoxylin and eosin. To assess the proliferation of
myofibroblast, we categorized the severity as grade 0, 1, 2, and 3 by estimating the cell
density and analyzed by Mann-Whitney U test. Results: 1) Invasion of inflammatory cells
and evidence of vasculitis were not apparent in any of the edge restenosis lesions or R
lesions. 2) In edge restenosis lesions, myofibroblasts were more scarce and active prolif-
Baseline (post procedure) Follow up (9 months)
RVD, mm 2.66+/-0.57 2.62+/-0.58
MLD, mm 2.07+/-0.66 1.61+/-0.98
DS, % 23.53+/-10.5 38.4+/-36.33
In-stent MLD, mm 1.99+/-0.56 1.23+/-0.76
In-stent DS, % 27.75+/-8.48 51.66+/-33.2
In-lesion late loss, mm 0.51+/-0.99
Binary Restenosis, % 35
MLD:minimal lumen diameter
RA group CB group P value
Pre MLD (mm) 0.76±0.37 0.84±0.41 0.30
Post MLD (mm) 2.59±0.39 2.69±0.53 0.30
Follow-up MLD (mm) 2.01±0.66 2.22±0.68 0.15
Acute gain (mm) 1.79±0.54 1.85±0.60 0.58
Late loss (mm) 0.35±0.52 0.54±0.60 0.25
Loss index 0.19±0.36 0.29±0.36 0.34
